Sutro Biopharma Inc (STRO) - News Archive

Sutro Biopharma has emerged as a front-runner in the development of innovative cancer therapies. At the upcoming American Association for Cancer Research (AACR) 2025 conference, the company will unveil preclinical findi...

On August 22, 2024, Sutro Biopharma, Inc. (NASDAQ: STRO), a South San Francisco-based clinical-stage oncology company, announced critical developments in its oncology portfolio centering around its pioneering site-speci...

Advancements in Antibody-Drug Conjugates by Sutro Biopharma: Enhancing Therapeutic Potential Sutro Biopharma, a biopharmaceutical company, recently presented significant advancements in the development of next-generatio...

SOUTH SAN FRANCISCO, Calif. On September 20, 2024, Sutro Biopharma, Inc. (NASDAQ: STRO) released a significant update following the disclosure that its Compensation Committee approved the grant of 60,000 restricted stoc...

Sutro Biopharma, a biopharmaceutical company renowned for its innovative drug discovery and development, recently shared updated data from its Phase 1b study of Luvelta (luveltamab tazevibulin) in combination with the w...

Sutro Biopharma Initiates REFRME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer SOUTH SAN FRANCISCO, Calif. Aug. 22, 2024 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a leadin...

Assessing the Impact of Sutro Biopharma s REFRME-O1 Trial on Patients with Platinum-Resistant Ovarian CancerIn recent news, Sutro Biopharma has announced the initiation of the randomized portion (Part 2) of the REFRME-O...

Sutro Biopharma Announces Pricing of $75 Million Underwritten OfferingSOUTH SAN FRANCISCO, Calif., April 02, 2024 - Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneeri...

Ipsen, a leading global pharmaceutical company, and Sutro Biopharma, a clinical-stage oncology-focused biotechnology company, have recently announced an exclusive global licensing agreement for the development and comme...

Luveltamab Tazevibulin, more commonly known as luvelta, exhibited complete remission in 42% of patients with CBF/GLIS Acute Myeloid Leukemia (AML) having 5% blasts, while an impressive 75% remission rate was noted in pe...